Skip to main content
Premium Trial:

Request an Annual Quote

Bioinformatics: With Donahue Leading Lion, Informatics Focus Reigns Again


If there’s anyone who knows how long it takes to change public perception of something, it’s Joe Donahue, de facto leader of Lion Bioscience. As chief business officer and North American president, Donahue has spent the last year and a half trying to hone the informatics company into a highly focused, well understood company. “The way the market is, the strategy of trying to be everything to everybody just wasn’t working,” he says.

Donahue joined Lion in April of 2003, after some time at Spotfire and 15 years at MDL Information Systems. Over the course of his time there, he says he watched Lion with great interest as the company started up, grew, and weathered the bad bioinformatics years. When the opportunity arose to join the firm, he recalls, “in Lion I saw a company that had an incredible amount of intellectual property [and] a great cash position. It had a franchise already.” But the IP wasn’t being used well and he thought the company had too much on its plate. The restructuring that he helped oversee “was not cutting back on what we were doing but saying of the three or four things we were doing, what’s the one thing we were really good at?”

With more than 30,000 users of Lion’s SRS platform, the answer seemed simple. “Lion really brings a unique mix of the informatics with the science — both the biology and the chemistry,” Donahue says. The service-shop business model and nascent drug discovery efforts went out the door — as well as a number of staff, bringing the company down to around 150 people. Lion held its first-ever user group meeting last year and got “really incredible feedback” from informatics customers, Donahue adds.

Still, that doesn’t mean Lion’s other forays were a waste. Through its service engagements with pharma companies like Bayer, the erstwhile informatics company developed a number of drug-discovery-oriented software modules that Lion is now rolling into its other product lines. Earlier this year, Lion released its new chemistry and bioinformatics modules to help pharmas with compound optimization and other areas.

Whether it’s Lion’s renewed focus or a coincidental economic upturn, something is clearly working, says Donahue. “In the past month we announced eight new SRS customers,” he says. “I don’t think we had eight in the past two years.”

Donahue is still spending much of his time on the road telling customers about Lion’s new look. Major customer targets are pharmaceutical companies, while anyone doing research and development is a good prospect, he says. If he plays his cards right, he aims to turn Lion into the “number one or number two informatics company in the life sciences domain.”

— Meredith Salisbury

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.